Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.
Type:
Grant
Filed:
October 4, 2011
Date of Patent:
May 19, 2020
Assignees:
International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.
Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.
Type:
Grant
Filed:
April 15, 2015
Date of Patent:
May 12, 2020
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Type:
Application
Filed:
November 22, 2019
Publication date:
March 12, 2020
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Type:
Application
Filed:
October 3, 2019
Publication date:
January 23, 2020
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: The present application relates to WT1 helper peptides consisting of an amino acid sequence of 9 to 30 amino acid residues including a sequence: KLSHL as part thereof, and combinations of a WT1 helper peptide and a conjugate of cancer antigen peptides.
Type:
Application
Filed:
November 29, 2017
Publication date:
January 16, 2020
Applicants:
SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Type:
Grant
Filed:
December 10, 2015
Date of Patent:
January 7, 2020
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
Type:
Application
Filed:
August 13, 2019
Publication date:
December 26, 2019
Applicant:
INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: A method of selecting patients highly responsive to WT1 vaccine and a therapeutic method for treating cancer involving said method of selection are provided, which method of selecting patients highly responsive to WT1 vaccine comprises: (a) isolating a biological sample containing CTL precursor cells from a test subject; (b) measuring the existence frequency or amount of WT1-specific CTL precursor cells in the biological sample of (a); and (c) deciding whether or not the measured value of (b) is high by comparison with that of healthy subject, and evaluating the responsiveness to WT1 vaccine.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
December 10, 2019
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
October 1, 2019
Assignee:
INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: Provided is a method for predicting a clinical effect on a subject in a WT1 peptide immunotherapy, said method comprising: a) a step for contacting a sample derived from the subject with WT1 antigen peptide or a variant thereof; and b) a step for detecting the binding of the sample to the WT1 antigen peptide or a variant thereof and thus measuring anti-WT1 antigen peptide IgG antibody titer existing in the sample, characterized in that an increase in the anti-WT1 antigen peptide IgG antibody titer in the subject determines the achievement of a favorable clinical effect. Also provided is a kit for performing the method according to the present invention, said kit containing WT1 antigen peptide or a variant thereof.
Type:
Grant
Filed:
May 12, 2014
Date of Patent:
September 10, 2019
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
August 20, 2019
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 18, 2019
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
Type:
Application
Filed:
October 17, 2018
Publication date:
January 31, 2019
Applicants:
SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.
Type:
Grant
Filed:
February 27, 2008
Date of Patent:
November 27, 2018
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a method of treating or preventing cancer, by administering a peptide consisting of 16-25 contiguous amino acids in the amino acid sequence of human WT1 of SEQ ID NO: 1, which has the amino acid sequence of SEQ ID NO: 24, an expression vector having a polynucleotide encoding said peptide or a cell containing the expression vector to a subject in need thereof.
Type:
Grant
Filed:
January 31, 2013
Date of Patent:
November 13, 2018
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.
Type:
Grant
Filed:
February 28, 2008
Date of Patent:
October 9, 2018
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide.
Type:
Application
Filed:
March 13, 2018
Publication date:
July 26, 2018
Applicant:
INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Abstract: The invention relates to a combination use of a WT1 antigen peptide or a pharmaceutically acceptable salt thereof and an immunomodulator for treating or preventing cancer.
Type:
Application
Filed:
May 19, 2016
Publication date:
May 24, 2018
Applicants:
Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Type:
Application
Filed:
December 10, 2015
Publication date:
December 28, 2017
Applicant:
International Institute of Cancer Immunology, Inc.
Abstract: Provided is a method for increasing the proportion of memory T cells in a T cell population, said method comprising a step of adding a modulator for the retinoid metabolic pathway and/or a modulator for the retinoic acid signaling system to the T cell population.
Type:
Application
Filed:
December 22, 2015
Publication date:
December 28, 2017
Applicant:
International Institute of Cancer Immunology, Inc.